Compare Gilead Sciences, Inc. (GILD) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs BlackRock TCP Capital Corp — how do they compare? Gilead Sciences, Inc. trades at $136.4 (market cap $168.35B), while BlackRock TCP Capital Corp trades at $3.88 (market cap $327.64M). The key difference: Gilead Sciences, Inc. is far larger — about 513.8× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (19.46%). Which is the better fit depends on your goals.
| GILD | TCPC | |
|---|---|---|
Market Cap | $168.35B | $327.64M |
Sector | Health | Financials |
52-Week High | $155.80 | $7.26 |
52-Week Low | $110.56 | $3.13 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | 19.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
TCPC trades at $3.88, down 1.52% today, with a bullish technical trend and neutral oscillators. Recent Q2 2026 earnings beat expectations at $0.22 per share, and the company announced a $523 million portfolio sale to reduce leverage. The stock shows a high P/S ratio of 70.7 but trades below book value with a P/B of 0.59. Dividends of $0.17 per share are scheduled for H1 and H2 2026.
Outlook is mixed: strategic moves and dividend yield near 8.8% offer value, but negative revenue, net losses, and a class action lawsuit pose risks. Analyst consensus leans hold, with 30.8% buy ratings. Further upside depends on successful execution of the strategic review and return to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
